Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported positive results from
a Phase 1b trial of APD334 to treat autoimmune diseases. Shares of the
biopharmaceutical leaped $2.53 to close at $5.85.
Arena Pharmaceuticals reports upbeat study results
January 07, 2015 at 15:16 PM EST
